Maze Therapeutics, Inc. (MAZE)
NASDAQ: MAZE · Real-Time Price · USD
26.46
+0.06 (0.23%)
May 29, 2026, 4:00 PM EDT - Market closed
Maze Therapeutics Employees
Maze Therapeutics had 141 employees as of December 31, 2025. The number of employees increased by 16 or 12.80% compared to the previous year.
Employees
141
Change (1Y)
16
Growth (1Y)
12.80%
Revenue / Employee
$141,844
Profits / Employee
-$869,092
Market Cap
1.46B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 141 | 16 | 12.80% |
| Dec 31, 2024 | 125 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,000 |
| Immatics | 711 |
| Immunocore Holdings | 524 |
| UroGen Pharma | 298 |
| KalVista Pharmaceuticals | 275 |
| Septerna | 130 |
| Inhibrx Biosciences | 110 |
| Bicara Therapeutics | 103 |
MAZE News
- 3 days ago - Maze Therapeutics to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 18 days ago - Maze Therapeutics reports Q1 EPS (45c), consensus (63c) - TheFly
- 18 days ago - Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights - GlobeNewsWire
- 18 days ago - Maze Therapeutics Earnings release: Q1 2026 - Filings
- 18 days ago - Maze Therapeutics Quarterly report: Q1 2026 - Filings
- 4 weeks ago - Maze Therapeutics Proxy statement: Proxy filing - Filings
- 4 weeks ago - Maze Therapeutics Proxy statement: Proxy filing - Filings
- 5 weeks ago - Maze Therapeutics priced offering of 5.54M shares of common stock at $23.50 - TheFly